Abstract
Chronic cavitary pulmonary aspergillosis (CCPA) has been associated with advanced lung diseases. Pulmonary sarcoidosis, a granulomatous inflammatory disorder, is associated with CCPA. We identified CCPA in 2% of cases in a large cohort of sarcoidosis patients. We found a lack of response to medical treatment and poor outcome in this subgroup.
Abbreviations
- ATS:
-
American Thoracic Society
- ERS:
-
European Respiratory Society
- BMI:
-
Body mass index
- %DLCO :
-
Percent predicted diffusion capacity of CO in ml/mmHg/min
- FEV1 :
-
Forced expiratory volume in 1 second
- FVC:
-
Forced vital capacity
- COPD:
-
Chronic obstructive pulmonary disease
- CCPA:
-
Chronic cavitary pulmonary aspergillosis
- EORTC/MSG:
-
European Organization for Research and Treatment of Cancer/Mycosis Study Group
- TLC:
-
Total lung capacity
References
Walsh TJ, Anaissie EJ, Denning DW et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360
Denning DW, Riniotis K, Dobrashian R et al (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280
Wollschlager C, Khan F (1984) Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest 86(4):585–588
[No authors listed] (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160(2):736–755
Marzouk K, Saleh S, Kannass M et al (2004) Interferon-induced granulomatous lung disease. Curr Opin Pulm Med 10(5):435–440
Girard N, Cottin V, Hot A et al (2004) Opportunistic infections and sarcoidosis. Rev Mal Respir 21(6 Pt 1):1083–1090
Baughman RP, Lower EE (2005) Fungal infections as a complication of therapy for sarcoidosis. QJM 98(6):451–456
Lachkar S, Dominique S, Thiberville L et al (2007) Aspergillosis and sarcoidosis. Rev Mal Respir 24(8):943–953
De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821
Samarakoon P, Soubani AO (2008) Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature. Chron Respir Dis 5(1):19–27
Muller NL, Kullnig P, Miller RR (1989) The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol 152(6):1179–1182
Glimp RA, Bayer AS (1983) Pulmonary aspergilloma. Diagnostic and therapeutic considerations. Arch Intern Med 143(2):303–308
Hance AJ, Basset F, Saumon G et al (1986) Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 465:643–656
Valeyre D, Soler P, Clerici C et al (1988) Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 43(7):516–524
Hanley ME, King TE Jr, Schwarz MI et al (1991) The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 144(5):1102–1106
Peros-Golubicic T, Ljubic S (1995) Cigarette smoking and sarcoidosis. Acta Med Croatica 49(4–5):187–193
Pfeifer AK, Lange P (2006) Pulmonary consequences of marijuana smoking. Ugeskr Laeger 168(18):1743–1746
Kagen SL, Kurup VP, Sohnle PG et al (1983) Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 71(4):389–393
Kagen SL (1981) Aspergillus: an inhalable contaminant of marijuana. N Engl J Med 304(8):483–484
Thornton CR (2010) Detection of invasive aspergillosis. Adv Appl Microbiol 70:187–216
Centeno-Lima S, de Lacerda JM, do Carmo JA et al (2002) Follow-up of anti-Aspergillus IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis. J Clin Lab Anal 16(3):156–162
Sole A, Salavert M (2009) Fungal infections after lung transplantation. Curr Opin Pulm Med 15(3):243–253
Bergeron A, Belle A, Sulahian A et al (2010) Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 137(2):410–415
Jennings TS, Hardin TC (1993) Treatment of aspergillosis with itraconazole. Ann Pharmacother 27(10):1206–1211
Campbell JH, Winter JH, Richardson MD et al (1991) Treatment of pulmonary aspergilloma with itraconazole. Thorax 46(11):839–841
De Beule K, De Doncker P, Cauwenbergh G et al (1988) The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982–1987). Mycoses 31(9):476–485
Dupont B (1990) Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 23(3 Pt 2):607–614
Soltanzadeh H, Wychulis AR, Sadr F et al (1977) Surgical treatment of pulmonary aspergilloma. Ann Surg 186(1):13–16
Guerra M, Santos N, Miranda J et al (2008) Surgical management of pulmonary aspergilloma. Rev Port Cir Cardiotorac Vasc 15(3):135–138
Chen JC, Chang YL, Luh SP et al (1997) Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 52(9):810–813
Brik A, Salem AM, Kamal AR et al (2008) Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 34(4):882–885
Caidi M, Kabiri H, Al Aziz S et al (2006) Surgical treatment of pulmonary aspergilloma. 278 cases. Presse Med 35(12 Pt 1):1819–1824
Camuset J, Nunes H, Dombret MC et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131(5):1435–1441
Felton TW, Baxter C, Moore CB et al (2010) Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 51(12):1383–1391
Lee KS, Kim HT, Kim YH et al (1993) Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. AJR Am J Roentgenol 161(4):727–731
Rumbak M, Kohler G, Eastrige C et al (1996) Topical treatment of life threatening haemoptysis from aspergillomas. Thorax 51(3):253–255
Kaplan J, Johns CJ (1979) Mycetomas in pulmonary sarcoidosis: non-surgical management. Johns Hopkins Med J 145(4):157–161
Idali F, Wikén M, Wahlström J et al (2006) Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J 27(3):451–459
Chaudhary N, Staab JF, Marr KA (2010) Healthy human T-cell responses to Aspergillus fumigatus antigens. PLoS One 5(2):e9036
Judson MA (2009) Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance. Chest 135(5):1358–1359
Acknowledgment
This work was supported by the Department of Medicine, Wayne State University School of Medicine (LS).
Disclosures
T. A. Pena, A. O. Soubani, and L. Samavati have no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pena, T.A., Soubani, A.O. & Samavati, L. Aspergillus Lung Disease in Patients with Sarcoidosis: A Case Series and Review of the Literature. Lung 189, 167–172 (2011). https://doi.org/10.1007/s00408-011-9280-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-011-9280-9